BR100 Increased By (0.24%)
BR30 Decreased By (-0.18%)
KSE100 Increased By (0.15%)
KSE30 Increased By (0.12%)
AGHA 7.84 Increased By ▲ 0.09 (1.16%)
BECO 5.20 Increased By ▲ 0.01 (0.19%)
BML 57.72 Decreased By ▼ -0.94 (-1.6%)
BOP 34.04 Increased By ▲ 0.35 (1.04%)
CNERGY 10.01 Decreased By ▼ -0.60 (-5.66%)
CSIL 5.32 Increased By ▲ 0.02 (0.38%)
FCCL 54.76 Increased By ▲ 1.02 (1.9%)
FFL 16.67 Increased By ▲ 0.21 (1.28%)
FNEL 1.24 Increased By ▲ 0.02 (1.64%)
KEL 7.43 Increased By ▲ 0.15 (2.06%)
KOSM 5.77 Increased By ▲ 0.13 (2.3%)
LOTCHEM 29.30 Decreased By ▼ -0.35 (-1.18%)
MLCF 94.70 Decreased By ▼ -1.66 (-1.72%)
NBP 202.90 Decreased By ▼ -0.63 (-0.31%)
NCPL 57.10 Increased By ▲ 0.25 (0.44%)
NPL 67.92 Increased By ▲ 0.61 (0.91%)
OGDC 316.50 Decreased By ▼ -1.72 (-0.54%)
PACE 10.72 Increased By ▲ 0.09 (0.85%)
PAEL 43.20 Increased By ▲ 1.43 (3.42%)
PIBTL 16.73 Decreased By ▼ -0.08 (-0.48%)
PPL 219.11 Decreased By ▼ -1.06 (-0.48%)
PRL 49.05 No Change ▼ 0.00 (0%)
PTC 70.55 Increased By ▲ 0.54 (0.77%)
SSGC 28.37 Decreased By ▼ -0.77 (-2.64%)
TBL 9.82 Increased By ▲ 0.05 (0.51%)
TELE 8.80 Decreased By ▼ -0.02 (-0.23%)
TPL 18.23 Increased By ▲ 1.06 (6.17%)
TPLP 13.25 Increased By ▲ 0.74 (5.92%)
TREET 22.73 Increased By ▲ 0.14 (0.62%)
TRG 60.00 Decreased By ▼ -0.22 (-0.37%)
By

BEIJING: Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday.

The regulator of the state medical insurance fund said authorities ordered the arrest of all suspects, but did not give details of the suspected violations or the size of funds involved.

It demanded that AstraZeneca China close loopholes in supervision of marketing activities, the NHSA added.

In a statement on Friday, the company said some employees in the southern city of Shenzhen had altered or participated in altering patients’ testing reports, and were suspected of medical insurance fraud.

The NHSA and public security ministry held a meeting with company officials in December to brief them on the investigation, it added.

“AstraZeneca China takes such employee misconduct seriously and welcomes the recommendations by the NHSA and MOPS,” it said.

An AstraZeneca spokesperson said all employees involved in the Shenzhen case were Chinese nationals.

Comments

Comments are closed for this article.